TAT-11: Innovation, Impact and Strategic Importance of Alpha Emitting Radionuclides

Ottawa, ON, Canada (UroToday.com) Oak Ridge National Laboratory was a pioneer in medical radioisotope production, and Dr. Mirzadeh began with a brief history. He noted the motivation for radiotherapy since the cost driver of cancer treatment comes mostly from the later stages after remission when radioisotopes tend to be used.

He discussed the problem of loss of daughters following the recoil of the first alpha decay. In the treatment of bone tumors with Ra225, about 30-40% of the Bi213 escapes from the bone. ORNL did much of the seminal work in encapsulating the radioisotopes in nanoparticles, particularly with LaPO4, to prevent daughters from escaping. Finally, he touched on isotope production, noting that ORNL can ship about 250 clinical doses of Ac225 per year.

Presented by: Saed Mirzadeh, PhD, Research Scientist and Corporate Fellow, Oak Ridge National Laboratory, Oak Ridge, Tennessee, United States

Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10) April 1 - April 4, 2019 - Ottawa, ON, Canada

Login